Methylnaltrexone Bromide
FDA-approved product (solution, subcutaneous), marketed as Methylnaltrexone Bromide, Relistor.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Constipation
- Opioid dependence
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Peripheral opioid receptor antagonists
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Methylnaltrexone Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
NCT00528970 · start 2007-10-17
Registered record
- Registry ID
- NCT00528970
- Conditions
- Ileus
- Interventions
- MOA-728; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-10-17
- Completion
- 2008-02-05
- Enrolment
- 374
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIleusInterventionMOA-728; PlaceboPhasePhase 3Registry statusCompletedStudy Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
NCT00547586 · start 2007-10
Registered record
- Registry ID
- NCT00547586
- Conditions
- Constipation
- Interventions
- N-methylnaltrexone bromide (MOA-728); placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2008-02
- Enrolment
- 122
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionConstipationInterventionN-methylnaltrexone bromide (MOA-728); placeboPhasePhase 2Registry statusCompletedStudy Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
NCT00529087 · start 2007-08
Registered record
- Registry ID
- NCT00529087
- Conditions
- Constipation
- Interventions
- N-methylnaltrexone bromide (MOA-728); placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-08
- Completion
- 2008-12
- Enrolment
- 460
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionConstipationInterventionN-methylnaltrexone bromide (MOA-728); placeboPhasePhase 3Registry statusCompletedStudy Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus
NCT00387309 · start 2006-12
Registered record
- Registry ID
- NCT00387309
- Conditions
- Post Operative Bowel Dysfunction
- Interventions
- Methylnaltrexone (MOA-728)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-12
- Completion
- 2007-11
- Enrolment
- 495
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost Operative Bowel DysfunctionInterventionMethylnaltrexone (MOA-728)PhasePhase 3Registry statusCompletedStudy of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
NCT00401375 · start 2006-10-31
Registered record
- Registry ID
- NCT00401375
- Conditions
- Post-Operative Ileus (POI)
- Interventions
- Methylnaltrexone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-10-31
- Completion
- 2008-02-29
- Enrolment
- 524
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost-Operative Ileus (POI)InterventionMethylnaltrexone; PlaceboPhasePhase 3Registry statusCompletedStudy of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide
NCT01366365 · start 2006-10
Registered record
- Registry ID
- NCT01366365
- Conditions
- Healthy Adults
- Interventions
- methylnaltrexone; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-10
- Completion
- 2006-11
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy AdultsInterventionmethylnaltrexone; placeboPhasePhase 1Registry statusCompletedEffects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan
NCT01367535 · start 2006-03
Registered record
- Registry ID
- NCT01367535
- Conditions
- Healthy Adults
- Interventions
- SC Methylnaltrexone (MNTX); IV Methylnaltrexone (MNTX); Oral Paroxetine; SC Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-03
- Completion
- 2006-08
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy AdultsInterventionSC Methylnaltrexone (MNTX); IV Methylnaltrexone (MNTX); Oral Paroxetine; SC PlaceboPhasePhase 1Registry statusCompletedEffect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization
NCT01363323 · start 2004-11
Registered record
- Registry ID
- NCT01363323
- Conditions
- Healthy Volunteers
- Interventions
- Methylnaltrexone (MNTX); Methylnaltrexone (MNTX); Methylnaltrexone (MNTX); Placebo; Moxifloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-11
- Completion
- 2005-02
- Enrolment
- 546
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionMethylnaltrexone (MNTX); Methylnaltrexone (MNTX); Methylnaltrexone (MNTX); Placebo +1 morePhasePhase 1Registry statusCompletedPharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function
NCT01367509 · start 2004-03
Registered record
- Registry ID
- NCT01367509
- Conditions
- Renal Impairment
- Interventions
- Methylnaltrexone (MNTX)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-03
- Completion
- 2005-06
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenal ImpairmentInterventionMethylnaltrexone (MNTX)PhasePhase 1Registry statusCompletedPharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
NCT01367522 · start 2004-03
Registered record
- Registry ID
- NCT01367522
- Conditions
- Liver Dysfunction
- Interventions
- SC Methylnaltrexone (MNTX)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-03
- Completion
- 2004-07
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLiver DysfunctionInterventionSC Methylnaltrexone (MNTX)PhasePhase 1Registry statusCompletedOpen-Label Treatment Extension of Protocol MNTX 302
NCT01367613 · start 2004-03
Registered record
- Registry ID
- NCT01367613
- Conditions
- Terminal Illness
- Interventions
- SC Methylnaltrexone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-03
- Completion
- 2006-01
- Enrolment
- 89
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTerminal IllnessInterventionSC MethylnaltrexonePhasePhase 3Registry statusCompletedStudy of Methylnaltrexone (MNTX) for the Relief of Constipation
NCT00402038 · start 2004-02
Registered record
- Registry ID
- NCT00402038
- Conditions
- Advance Illness Patients With OIC
- Interventions
- SC Methylnaltrexone; SC Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2005-10
- Enrolment
- 134
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvance Illness Patients With OICInterventionSC Methylnaltrexone; SC PlaceboPhasePhase 3Registry statusCompletedPharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
NCT01366352 · start 2004-02
Registered record
- Registry ID
- NCT01366352
- Conditions
- Normal Volunteers
- Interventions
- MNTX tablet (Formulation 1); MNTX tablet (Formulation 2)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2004-03
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNormal VolunteersInterventionMNTX tablet (Formulation 1); MNTX tablet (Formulation 2)PhasePhase 1Registry statusCompletedTolerance and Pharmacokinetics Study of MNTX Tablets
NCT01366339 · start 2003-10
Registered record
- Registry ID
- NCT01366339
- Conditions
- Normal Healthy Volunteers
- Interventions
- Oral methylnaltrexone; Oral placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2003-12
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNormal Healthy VolunteersInterventionOral methylnaltrexone; Oral placeboPhasePhase 1Registry statusCompletedIntravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus
NCT01367548 · start 2003-07
Registered record
- Registry ID
- NCT01367548
- Conditions
- Postoperative Ileus
- Interventions
- IV Methylnaltrexone (MNTX); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-07
- Completion
- 2004-12
- Enrolment
- 65
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative IleusInterventionIV Methylnaltrexone (MNTX); PlaceboPhasePhase 2Registry statusCompleted